18 September 2013

£25m to kick-start 'industrial revolution' in regenerative medicine

The Sanger Institute contributes sequencing capabilities to new pluripotent stem cell Hub

UK Regenerative Medicine Platform

UK Regenerative Medicine Platform [Medical Research Council]

The Wellcome Trust Sanger Institute is participating in a £25m programme to develop regenerative medicine therapies for a range of applications, including Parkinson's disease, cardiovascular disease, wound and musculoskeletal repair, eye disorders and deafness.

The Sanger Institute will play a key role in the new £4.5 million 'Hub' for pluripotent stem cell research that is being established with the help of the funding as part of the UK Regenerative Medicine Platform (UKRMP), funded by the Biotechnology and Biological Sciences Research Council (BBSRC), Engineering and Physical Sciences Research Council (EPSRC) and the Medical Research Council (MRC). The capabilities and pipelines of the Sanger Institute will provide genomic and epigenomic analysis of pluripotent cells used in treatments as a quality control measure.

"We will sequence the DNA of the pluripotent cells to check that there aren't unwanted genetic changes that could pose potential dangers," said Dr Kosuke Yusa from the Sanger Institute. "We have an important role to play in ensuring the veracity of cells using our high-throughput-next-generation sequencing technologies."

A further £20m of capital funding from the Medical Research Council will provide new state-of-the-art facilities and equipment to support the work of the UKRMP and the wider regenerative medicine research community.

At the moment, experimental cell therapies are made in small numbers, usually by laboratory researchers. To ultimately be able to treat the thousands of patients who could benefit from regenerative medicine, scientists need to be able to reliably manufacture millions of cells under uniform and controlled conditions.

" Pluripotent stem cells represent a vital step in translating genomic understanding into medical treatments. "

Professor Sir Mike Stratton

The aim of the Hub is to lay the initial foundations for scaling up the production of cell-based therapies from a 'cottage industry' to a robust system that will be suitable for clinical practice. It will develop a set of protocols for manufacturing cell therapies that meet the requirements of doctors, regulators and industry. This will entail making sure cells do not undergo unwanted genetic changes, improving differentiation so that scientist can reliably turn 'blank' cells into the type of cell they want and ensuring the right quality control systems are in place so that manufactured cell therapies are safe and suitable for use in human treatments.

Initially they will focus on two disease areas - Parkinson's disease and deafness - where efforts to develop cell therapies are already well underway. The researchers will work closely with commercial companies from the start to ensure that the procedures they develop are commercially viable.

"Pluripotent stem cells represent a vital step in translating genomic understanding into medical treatments," said Professor Sir Mike Stratton, Director of the Sanger Institute. "We are delighted to bring our expertise to this exciting new initiative, which fits very well with our already established programmes in cellular differentiation."

The Hub will be led by the Universities of Sheffield, Loughborough and Cambridge and builds on existing capabilities within MRC and EPSRC Centres and the UK Stem Cell Bank. It will collaborate with the Wellcome Trust Sanger Institute and Babraham Institute and will complement the work of the existing UKRMP research Hubs.

"The pluripotency hub brings together for the first time in the UK, researchers with the range of expertise necessary to develop the processes needed to take these cells from laboratory-based research to the commercial manufacture of safe, effective and reproducible products for use in regenerative medicine." said Professor Peter Andrews, from the Centre for Stem Cell Biology at the University of Sheffield.

Notes to Editors

The Medical Research Council

The Medical Research Council has been at the forefront of scientific discovery to improve human health. Founded in 1913 to tackle tuberculosis, the MRC now invests taxpayers' money in some of the best medical research in the world across every area of health. MRC-funded scientists tackle some of the greatest health problems facing humanity in the 21st century, from the rising tide of chronic diseases associated with ageing to the threats posed by rapidly mutating micro-organisms.


University of Sheffield

A member of the Russell Group, the University of Sheffield has a reputation for world-class teaching and research excellence across a wide range of disciplines. The University of Sheffield has been named University of the Year in the Times Higher Education Awards 2011 for its exceptional performance in research, teaching, access and business performance. In addition, the University has won four Queen's Anniversary Prizes (1998, 2000, 2002, 2007), recognising the outstanding contribution by universities and colleges to the United Kingdom's intellectual, economic, cultural and social life.


The Wellcome Trust Sanger Institute

The Wellcome Trust Sanger Institute is one of the world's leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.


The Wellcome Trust

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests.


Contact the Press Office

Mark Thomson Senior Media and Public Relations Officer
Wellcome Trust Sanger Institute, Hinxton, Cambs, CB10 1SA, UK

Tel +44 (0)1223 492 384
Mobile +44 (0)7753 775 397
Fax +44 (0)1223 494 919
Email press.office@sanger.ac.uk

* quick link - http://q.sanger.ac.uk/t6wtyg8t